InvivydIVVD +2.49%27 Days Payable is 697.02 as of Mar. 2026, which is 57% below its 10-year median of 1,626.90. GuruFocus rates IVVD with a GF Score™ of 27/100. The stock has 3 warning signs investors should review. Among 707 Biotechnology companies, Invivyd ranks better than 86.99% on this metric.
Invivyd's average Accounts Payable for the
three
months ended in Mar. 2026 was $7.88 Mil. Invivyd's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $1.03 Mil.
Hence, Invivyd's Days Payable for the
three
months ended in Mar. 2026 was 697.02.
The historical rank and industry rank for Invivyd's Days Payable or its related term are showing as below:
IVVD'
s Days Payable Range Over the Past 10 Years
Min: 1122.48 Med: 1626.9 Max: 2075.51
Current: 1122.48
During the past 6 years, Invivyd's highest Days Payable was 2075.51. The lowest was 1122.48. And the median was 1626.90.
IVVD's Days Payable is ranked better than 86.99% of 707
companies
in the Biotechnology industry
Industry Median: 113.76
vs IVVD: 1122.48
Invivyd's Days Payable
declined
from Mar. 2025 (1,049.65) to Mar. 2026 (697.02).
It may suggest that Invivydaccelerated paying its suppliers.
Invivyd Days Payable Related Terms
Invivyd Days Payable Historical Data
* Premium members only.
The historical data trend for Invivyd's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Invivyd's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invivyd Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Invivyd's Days Payable distribution charts can be found below:
* The bar in red indicates where Invivyd's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Invivyd's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invivyd (IVVD) has a Days Payable of 697.02 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Invivyd and its competitors. This is 57% below median its historical median of 1,626.90. Over the past decade, Invivyd's Days Payable has ranged from 1,122.48 to 2,075.51. According to the industry distribution chart, Invivyd ranks #92 out of 707 companies in the Biotechnology industry, placing it in the top 13%.
Is Invivyd's Days Payable too high?
Invivyd's current Days Payable of 697.02 is 57% below median its 10-year median of 1,626.90. Over the past 10 years, this metric has ranged from a low of 1,122.48 to a high of 2,075.51. The Biotechnology industry median Days Payable is 113.76. Invivyd's value of 697.02 is 512.7% above this industry median. Based on the distribution chart, Invivyd ranks #92 out of 707 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Invivyd has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Invivyd's Days Payable compare to RCKT and LCTX?
According to the Biotechnology industry distribution chart, Invivyd ranks #92 out of 707 companies for Days Payable. This places Invivyd in the top 13% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.76. Invivyd's value of 697.02 is 512.7% above this benchmark. Historically, Invivyd's own Days Payable has ranged from 1,122.48 to 2,075.51 over the past decade. While the company's 10-year median is 1,626.90 vs. the industry median of 113.76, Invivyd has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Invivyd's current Days Payable of 697.02 is 512.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Invivyd and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invivyd's current Days Payable is 697.02, which is 57% below median its own 10-year median of 1,626.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invivyd stock overvalued right now?
Invivyd (IVVD) has a current Days Payable of 697.02. The current Days Payable is 697.02, which is 57% below median its 10-year median of 1,626.90 and 512.7% above the Biotechnology industry median of 113.76. Invivyd's overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Invivyd (IVVD), the current Days Payable is 697.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.
27GF Score
Get the complete analysis for IVVD
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IVVD has been successfully added to your 
